建发致新更新财务资料，负债率高企，分红2亿后欲揽2亿补流

Core Viewpoint - Shanghai Jianda Zhixin Medical Technology Group Co., Ltd. (referred to as "Jianda Zhixin") has faced delays in its IPO process, having not submitted registration documents for over a year and a half after passing the listing committee meeting in November 2023 [1][3]. Financial Performance - Jianda Zhixin's revenue from 2020 to the first half of 2023 was 8.542 billion, 10.024 billion, 11.882 billion, and 7.499 billion respectively, while net profit attributable to the parent company was 160 million, 167 million, 174 million, and 89.64 million respectively [4]. - The company's total assets as of June 30, 2023, were approximately 1.042 billion, with a debt ratio of 87.76%, significantly higher than the industry average [5][8]. Business Operations - Jianda Zhixin operates as a national high-value medical device distributor, primarily engaged in direct sales and distribution of medical devices, and providing centralized operation services for medical consumables to hospitals [2]. - The company has experienced a decline in revenue from its main cardiovascular intervention products, which accounted for 81.93%, 70.53%, 63.90%, and 60.77% of its main business income from 2020 to 2023 [6][7]. Cash Flow and Dividends - Despite a total cash dividend exceeding 200 million over three years, Jianda Zhixin has reported negative operating cash flows, with net cash flow from operating activities being -120.15 million, -6.328 billion, -6.279 billion, and -5.041 billion respectively [10][12]. - The company plans to raise a total of 484 million, with 240 million allocated for replenishing working capital, which constitutes 49.59% of the total fundraising [13][14].